MIT Sloan Management Review and Boston Consulting Group (BCG)
102 episodes
1 month ago
Why do only 10% of companies succeed with AI? In this series by MIT SMR and BCG, we talk to the leaders who've achieved big wins with AI in their companies and learn how they did it. Hear what gets experts from companies like NASA, Github, and others excited to do their jobs every day and what they consider the keys to their success.
All content for Me, Myself, and AI is the property of MIT Sloan Management Review and Boston Consulting Group (BCG) and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Why do only 10% of companies succeed with AI? In this series by MIT SMR and BCG, we talk to the leaders who've achieved big wins with AI in their companies and learn how they did it. Hear what gets experts from companies like NASA, Github, and others excited to do their jobs every day and what they consider the keys to their success.
Training AI to Detect Disease: Stand Up To Cancer’s Julian Adams
Me, Myself, and AI
31 minutes
2 weeks ago
Training AI to Detect Disease: Stand Up To Cancer’s Julian Adams
Julian Adams tried but didn’t succeed at retirement after a productive career as a medical chemist with several U.S. Food and Drug Association approvals of cancer-related treatments, including cell therapy for bone marrow transplantation. Soon after, his participation in a Stand Up To
Cancer advisory group led to his appointment as the nonprofit’s president and CEO.
The research organization raises money to advance the diagnosis of numerous cancers. Given rapid technological advancements, our podcast hosts were eager to invite Julian on the show to share how Stand Up To Cancer uses artificial intelligence to aid in this pursuit. Read the episode transcript here.
For more information on Stand Up To Cancer and how to donate
to the organization, please visit this website.
Guest bio
Julian Adams, president and CEO of Stand Up To Cancer, is among the world’s foremost oncology researchers. He was previously CEO of biopharmaceutical company Gamida Cell and president of R&D at Infinity Pharmaceuticals, where he oversaw development of small molecule drugs to treat cancer. He has also held roles at Millennium Pharmaceuticals, Boehringer Ingelheim, LeukoSite, and ProScript.
Adams’s recognitions include the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, an anti-cancer drug; the 2012 C. Chester Stock Award Lectureship from Memorial Sloan Kettering Cancer Center; and the 2001 Ribbon of Hope Award for Velcade from the International Myeloma Foundation. He holds more than 40 patents and has authored more than 130 papers and book chapters. He received his bachelor’s degree and an honorary doctor of science degree from McGill University and his Ph.D. from MIT in synthetic organic chemistry.
Me, Myself, and AI is a collaborative podcast from MIT Sloan Management Review and Boston Consulting Group and is hosted by Sam Ransbotham and Shervin Khodabandeh. Our engineer is David Lishansky, and the executive producer is Allison Ryder.
Stay in touch with us by joining our LinkedIn group, AI for Leaders at mitsmr.com/AIforLeaders or by following Me, Myself, and AI on LinkedIn.
We encourage you to rate and review our show. Your comments may be used in Me, Myself, and AI materials.
Me, Myself, and AI
Why do only 10% of companies succeed with AI? In this series by MIT SMR and BCG, we talk to the leaders who've achieved big wins with AI in their companies and learn how they did it. Hear what gets experts from companies like NASA, Github, and others excited to do their jobs every day and what they consider the keys to their success.
